GlassScriptPhysician profile
Leif E Christiansen
NPI 1710988092
$9,765.77
in general payments reported to CMS, 2019-2025
55 companies · $1,632 in 2025
The $1,632 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,042 · 2020: $1,002 · 2021: $1,315 · 2022: $1,616 · 2023: $1,473 · 2024: $1,685 · 2025: $1,632.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,783 · Education: $6.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,783.46 |
| Education | $6.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,538.66 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $1,118.20 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Abbvie INC. | $893.45 | 2019-2025 | Qulipta, Ubrelvy, Viberzi |
| Lilly USA, LLC | $684.49 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $533.51 | 2019-2025 | Evenity, Prolia, Prolia |
| Pfizer INC. | $523.85 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $464.63 | 2019-2025 | |
| Glaxosmithkline, LLC. | $422.29 | 2019-2025 | Shingrix, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $380.23 | 2019-2025 | Jardiance, Tradjenta, Synjardy |
| Otsuka America Pharmaceutical, INC. | $304.30 | 2019-2025 | Rexulti, Abilify Maintena |
| Bayer Healthcare Pharmaceuticals INC. | $246.68 | 2021-2023 | |
| Astellas Pharma US INC | $207.46 | 2019-2024 | Veozah, Myrbetriq |
| Phathom Pharmaceuticals, INC. | $191.82 | 2024-2025 | Voquezna |
| Amarin Pharma, INC. | $138.22 | 2019-2022 | |
| Medtronic, INC. | $134.32 | 2023-2024 | Minimed 780g |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Leif Christiansen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.